| Name | Title | Contact Details |
|---|---|---|
James Fink |
Director of Facilities, EHandS and Security | Profile |
M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.
A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2015, revenues reached €1.965 billion with 90% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
The Laboratory for Advanced Medicine, Inc. (LAM) is a bio-pharmaceutical company dedicated to developing revolutionary non-invasive, non-toxic technologies for disease diagnosis and intervention, with an emphasis on cancer.
Princeton Separations Inc is a Freehold, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.